Download .pdf, .docx, .epub, .txt
Did you like this example?


“My ideas of a better ordered world is one in which medical discoveries would be free of patents and there would be no profiteering from life or death”[i] – Indira Gandhi

Intellectual property regimes are usually assumed to exert positive enticements on technological innovation. However, given the serious nature of access to critical health technologies for most of the world’s population, it is worth revisiting this presumption for health technologies. The reasons contributing to this situation range from weak supply systems to exorbitant prices. The factors that stimulate innovation are often biased against conditions that excessively affect the populations of developing nations. For example, there were only 11 medicines for tropical diseases amongst1325 new medicines launched between 1975 and 1997.[ii] The amalgamation of market failure and under-investment by the public sector discourages the innovation in developing countries. The procedure of bringing a new product to the market is both costly and lengthy. Due to the resource implications and the uncertainties involved, creating an environment favorable to successful innovation is indispensable.

Therefore the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) took the initiative to undertake the strenuous task of balancing private and public interests. On one side, it protects the interests of the pharmaceutical companies that invest heavily in research and development of drugs, while on the other hand, it allows nations that are a member of World Trade Organisation (WTO) to support public health in their respective countries. It allows developing and least developed countries to have the benefit of a moratorium[iii] on implementing pharmaceutical patents until the years 2005 and 2016 respectively. However, this is of little consolation[iv]since the dispensation has been effectively neutralized by industrially developed nations. For example, a number of pharmaceutical companies challenged the South African legislation authorized the minister of health to issue compulsory license under certain circumstances. The law was based on the hypothesis that expensive drugs were unaffordable to large sections of society and that the following lack of access to drugs was leading to a serious health crisis within the country. The action of the pharmaceutical industry against the South African initiative led to widespread criticism of the TRIPS agreement by the developing world, NGOs and human rights activists led to the Doha Declaration on Public Health of November 2001. Once TRIPS was adopted in 1994, developing and least developed countries were obliged to effect changes in their patent laws in accordance with the agreement. But, in the meantime, they were to provide Exclusive Marketing Rights (EMR)[v] to those who had obtained patents in other member countries on or after the date of the entry into force of the TRIPS agreement. They were also required to create a mechanism to enable the filing of patent applications pending the expiry of the moratorium on the implementation of pharmaceutical patents. The objective of the Doha Declaration on the TRIPS Agreement and Public Health was to clarify the official stand on certain provisions of TRIPS relating to public health.

Do you want to see the Full Version?

View full version

Having doubts about how to write your paper correctly?

Our editors will help you fix any mistakes and get an A+!

Get started
Leave your email and we will send a sample to you.
Thank you!

We will send an essay sample to you in 2 Hours. If you need help faster you can always use our custom writing service.

Get help with my paper
Sorry, but copying text is forbidden on this website. You can leave an email and we will send it to you.